

Mario Thevis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3130706/publications.pdf>

Version: 2024-02-01

433
papers

12,558
citations

30070

54
h-index

69250

77
g-index

458
all docs

458
docs citations

458
times ranked

5964
citing authors

#	ARTICLE	IF	CITATIONS
1	Data from a microdosed recombinant human erythropoietin administration study applying the new biotinylated clone AE7A5 antibody and a further optimized sarcosyl polyacrylamide gel electrophoresis protocol. <i>Drug Testing and Analysis</i> , 2023, 15, 163-172.	2.6	10
2	Risk of unintentional antidoping rule violations by consumption of hemp products. <i>Drug Testing and Analysis</i> , 2023, 15, 27-41.	2.6	5
3	Investigations in carbon isotope ratios of seized testosterone and boldenone preparations. <i>Drug Testing and Analysis</i> , 2022, 14, 514-518.	2.6	6
4	First use of the anti- α 2vWF nanobody caplacizumab to treat iTTP in pregnancy. <i>British Journal of Haematology</i> , 2022, 196, .	2.5	17
5	Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 649-659.	3.6	9
6	Urinary phenylethylamine metabolites as potential markers for sports drug testing purposes. <i>Biomedical Chromatography</i> , 2022, 36, e5274.	1.7	4
7	Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 1151-1162.	3.7	12
8	Annual banned substance review: Analytical approaches in human sports drug testing 2020/2021. <i>Drug Testing and Analysis</i> , 2022, 14, 7-30.	2.6	17
9	Probing for factors influencing exhaled breath drug testing in sports – Pilot studies focusing on the tested individual's tobacco smoking habit and sex. <i>Rapid Communications in Mass Spectrometry</i> , 2022, 36, e9262.	1.5	4
10	Investigations into the In Vitro Metabolism of hGH and IGF-I Employing Stable-Isotope-Labeled Drugs and Monitoring Diagnostic Immonium Ions by High-Resolution/High-Accuracy Mass Spectrometry. <i>Metabolites</i> , 2022, 12, 146.	2.9	3
11	Assessing human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches. <i>Analytica Chimica Acta</i> , 2022, 1202, 339661.	5.4	7
12	Phase I-metabolism studies of the synthetic cannabinoids PX-1 and PX-2 using three different in vitro models. <i>Forensic Toxicology</i> , 2022, 40, 244-262.	2.4	3
13	Probing for the presence of semenogelin in human urine by immunological and chromatographic-mass spectrometric methods in the context of sports drug testing. <i>Analytical Science Advances</i> , 2022, 3, 21-28.	2.8	7
14	Stereoisomers in sports drug testing: Analytical strategies and applications. <i>Journal of Chromatography A</i> , 2022, 1674, 463154.	3.7	4
15	Analysis of dried blood spots is a feasible alternative for detecting ephedrine in doping control. <i>Drug Testing and Analysis</i> , 2022, 14, 1685-1695.	2.6	4
16	Investigations on the <i>in vivo</i> metabolism of 5 α -androstane-17-one. <i>Rapid Communications in Mass Spectrometry</i> , 2022, 36, .	1.5	2
17	Determination and enantioselective separation of zilpaterol in human urine after mimicking consumption of contaminated meat using high-performance liquid chromatography with tandem mass spectrometry techniques. <i>Rapid Communications in Mass Spectrometry</i> , 2022, 36, .	1.5	4
18	Annual banned substance review: Analytical approaches in human sports drug testing 2019/2020. <i>Drug Testing and Analysis</i> , 2021, 13, 8-35.	2.6	22

#	ARTICLE	IF	CITATIONS
19	An in vitro assay approach to investigate the potential impact of different doping agents on the steroid profile. <i>Drug Testing and Analysis</i> , 2021, 13, 916-928.	2.6	8
20	Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use. <i>Drug Testing and Analysis</i> , 2021, 13, 539-549.	2.6	18
21	Probing for the presence of doping agents in exhaled breath using chromatographic/mass spectrometric approaches. <i>Rapid Communications in Mass Spectrometry</i> , 2021, 35, e8939.	1.5	9
22	Investigation of Equine In Vivo and In Vitro Derived Metabolites of the Selective Androgen Receptor Modulator (SARM) ACP-105 for Improved Doping Control. <i>Metabolites</i> , 2021, 11, 85.	2.9	9
23	Mass spectrometric identification and characterization of urinary metabolites of isopropylornosynephrine for doping control purposes. <i>Analytical Science Advances</i> , 2021, 2, 334-341.	2.8	4
24	Comprehensive insights into the formation of metabolites of the ghrelin mimetics capromorelin, macimorelin and tabimorelin as potential markers for doping control purposes. <i>Biomedical Chromatography</i> , 2021, 35, e5075.	1.7	5
25	Do dried blood spots have the potential to support result management processes in routine sports drug testing? Part 2: Proactive sampling for follow-up investigations concerning atypical or adverse analytical findings. <i>Drug Testing and Analysis</i> , 2021, 13, 505-509.	2.6	19
26	Detection of anti-SARS-CoV-2 antibodies in dried blood spots utilizing manual or automated spot extraction and electrochemiluminescence immunoassay (ECLIA). <i>Analytical Science Advances</i> , 2021, 2, 440.	2.8	4
27	Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	28
28	Facilitated Qualitative Determination of Insulin, Its Synthetic Analogs, and C-Peptide in Human Urine by Means of LC-HRMS. <i>Metabolites</i> , 2021, 11, 309.	2.9	12
29	Current Insights into the Steroidal Module of the Athlete Biological Passport. <i>International Journal of Sports Medicine</i> , 2021, 42, 863-878.	1.7	14
30	Carbon isotope ratios of endogenous steroids found in human serum method development, validation, and reference population-derived thresholds. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 5655-5667.	3.7	9
31	Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2021, 44, 733-744.	1.3	3
32	Broadening the Horizon of Antidoping Analytical Approaches Using Dried Blood Spots. <i>Clinical Chemistry</i> , 2021, 67, 1041-1043.	3.2	3
33	Stanozolol-N-glucuronide metabolites in human urine samples as suitable targets in terms of routine anti-doping analysis. <i>Drug Testing and Analysis</i> , 2021, 13, 1668-1677.	2.6	10
34	Depletion of clomiphene residues in eggs and muscle after oral administration to laying hens. <i>Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment</i> , 2021, 38, 1875-1882.	2.3	6
35	Meldonium residues in milk: A possible scenario for inadvertent doping in sports?. <i>Drug Testing and Analysis</i> , 2021, 13, 1906-1910.	2.6	9
36	Mass spectrometric characterization of urinary hydrafinil metabolites for routine doping control purposes. <i>Drug Testing and Analysis</i> , 2021, 13, 1915-1920.	2.6	5

#	ARTICLE	IF	CITATIONS
37	Detection of undeclared doping substances in nutritional supplements in the context of follow-up investigations concerning adverse analytical findings. <i>Drug Testing and Analysis</i> , 2021, 13, 1911-1914.	2.6	8
38	Organ-on-a-chip: Determine feasibility of a human liver microphysiological model to assess long-term steroid metabolites in sports drug testing. <i>Drug Testing and Analysis</i> , 2021, 13, 1921-1928.	2.6	17
39	Metabolism of oral turinabol by the human brain cholesterol 24-hydroxylase CYP46A1. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 212, 105927.	2.5	0
40	Chromatographic-mass spectrometric analysis of the urinary metabolite profile of chlorphenesin observed after dermal application of chlorphenesin-containing sunscreen. <i>Rapid Communications in Mass Spectrometry</i> , 2021, 35, e9183.	1.5	8
41	Recent advances in identifying and utilizing metabolites of selected doping agents in human sports drug testing. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 205, 114312.	2.8	15
42	Effect of a Single Bout of Aerobic Exercise on Kynurenine Pathway Metabolites and Inflammatory Markers in Prostate Cancer Patients – A Pilot Randomized Controlled Trial. <i>Metabolites</i> , 2021, 11, 4.	2.9	7
43	Determination of ghrelin and desacyl ghrelin in human plasma and urine by means of LC-MS/MS for doping controls. <i>Drug Testing and Analysis</i> , 2021, , .	2.6	3
44	Sensitive detection of testosterone and testosterone prohormone administrations based on urinary concentrations and carbon isotope ratios of androsterone and etiocholanolone. <i>Drug Testing and Analysis</i> , 2021, 13, 1835-1851.	2.6	4
45	Sports drug testing and the athletes' exposome. <i>Drug Testing and Analysis</i> , 2021, 13, 1814-1821.	2.6	27
46	Chiral analysis of selected enantiomeric drugs relevant in doping controls. <i>Journal of Chromatography Open</i> , 2021, 1, 100017.	2.2	4
47	The 39th Manfred Donike workshop on doping analysis. <i>Drug Testing and Analysis</i> , 2021, 13, 1812-1813.	2.6	1
48	Akzidentelle Einnahme von Mifegyne im dritten Trimenster – ein Fallbericht. <i>Zeitschrift Fur Geburtshilfe Und Neonatologie</i> , 2021, 225, .	0.4	0
49	Introduction of a PEGylated EPO conjugate as internal standard for EPO analysis in doping controls. <i>Drug Testing and Analysis</i> , 2021, , .	2.6	3
50	Androgens, sports, and detection strategies for anabolic drug use. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, , 101609.	4.7	6
51	Analytical Approaches in Human Sports Drug Testing: Recent Advances, Challenges, and Solutions. <i>Analytical Chemistry</i> , 2020, 92, 506-523.	6.5	39
52	Solid-phase extraction-liquid chromatography-tandem mass spectrometry method for the qualitative analysis of 61 synthetic cannabinoid metabolites in urine. <i>Drug Testing and Analysis</i> , 2020, 12, 27-40.	2.6	17
53	Annual banned-substance review – Analytical approaches in human sports drug testing. <i>Drug Testing and Analysis</i> , 2020, 12, 7-26.	2.6	22
54	Elevated urinary cobalt concentrations identified in routine doping controls can originate from vitamin B ₁₂ . <i>Rapid Communications in Mass Spectrometry</i> , 2020, 34, e8649.	1.5	8

#	ARTICLE	IF	CITATIONS
55	Tainted toothpaste – Analytical investigation into an unusual adverse finding. <i>Drug Testing and Analysis</i> , 2020, 12, 570-572.	2.6	6
56	Simplified quantification of insulin, its synthetic analogs and C-peptide in human plasma by means of LC-MS/MS. <i>Drug Testing and Analysis</i> , 2020, 12, 382-390.	2.6	26
57	Fatalities associated with NPS stimulants in the Greater Cologne area. <i>International Journal of Legal Medicine</i> , 2020, 134, 229-241.	2.2	7
58	Identification of metabolites of peptide-derived drugs using an isotope-labeled reporter ion screening strategy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 690-700.	2.3	8
59	Detection of follistatin-based inhibitors of the TGF- β signaling pathways in serum/plasma by means of LC-MS/MS and Western blotting. <i>Drug Testing and Analysis</i> , 2020, 12, 1636-1648.	2.6	8
60	Sport doping detection in focus: A perspective from Prof. Dr Mario Thevis. <i>Analytical Science Advances</i> , 2020, 1, 141-142.	2.8	0
61	First Steps toward Uncovering Gene Doping with CRISPR/Cas by Identifying SpCas9 in Plasma via HPLC-MS/MS. <i>Analytical Chemistry</i> , 2020, 92, 16322-16328.	6.5	13
62	Dietary Supplement and Food Contaminations and Their Implications for Doping Controls. <i>Foods</i> , 2020, 9, 1012.	4.3	74
63	Paper spray mass spectrometry – A potential complementary technique for the detection of polar compounds in sports drug testing. <i>Drug Testing and Analysis</i> , 2020, 12, 1658-1665.	2.6	13
64	Elimination profiles of microdosed ostarine mimicking contaminated products ingestion. <i>Drug Testing and Analysis</i> , 2020, 12, 1570-1580.	2.6	23
65	Implementation of the HIF activator IOX-2 in routine doping controls – Pilot study data. <i>Drug Testing and Analysis</i> , 2020, 12, 1614-1619.	2.6	6
66	The 38 th Manfred Donike workshop on doping analysis. <i>Drug Testing and Analysis</i> , 2020, 12, 1541-1542.	2.6	0
67	Analysis of cobalt for human sports drug testing purposes using ICP and LC-ICP-MS. <i>Drug Testing and Analysis</i> , 2020, 12, 1666-1672.	2.6	15
68	Excretion of 19-norandrosterone after consumption of boar meat. <i>Drug Testing and Analysis</i> , 2020, 12, 1581-1586.	2.6	7
69	Can dried blood spots (DBS) contribute to conducting comprehensive SARS-CoV-2 antibody tests?. <i>Drug Testing and Analysis</i> , 2020, 12, 994-997.	2.6	37
70	Single-dose administration of clenbuterol is detectable in dried blood spots. <i>Drug Testing and Analysis</i> , 2020, 12, 1366-1372.	2.6	16
71	Identification of Trenbolone Metabolites Using Hydrogen Isotope Ratio Mass Spectrometry and Liquid Chromatography/High Accuracy/High Resolution Mass Spectrometry for Doping Control Analysis. <i>Frontiers in Chemistry</i> , 2020, 8, 435.	3.6	11
72	Do dried blood spots (DBS) have the potential to support result management processes in routine sports drug testing?. <i>Drug Testing and Analysis</i> , 2020, 12, 704-710.	2.6	33

#	ARTICLE	IF	CITATIONS
73	Detecting the misuse of 7 α -DHEA by means of carbon isotope ratio mass spectrometry in doping control analysis. <i>Rapid Communications in Mass Spectrometry</i> , 2020, 34, e8776.	1.5	8
74	Inter-Laboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured Intact by Mass Spectrometry. <i>Clinical Chemistry</i> , 2020, 66, 579-586.	3.2	17
75	Acute hypertrophic but not maximal strength loading transiently enhances the kynurenine pathway towards kynurenic acid. <i>European Journal of Applied Physiology</i> , 2020, 120, 1429-1436.	2.5	13
76	Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 3765-3777.	3.7	40
77	Exercise and the Kynurenine pathway: Current state of knowledge and results from a randomized cross-over study comparing acute effects of endurance and resistance training. <i>Exercise Immunology Review</i> , 2020, 26, 24-42.	0.4	31
78	Erythropoietic effects of low-dose cobalt application. <i>Drug Testing and Analysis</i> , 2019, 11, 200-207.	2.6	18
79	Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone). <i>Forensic Science International</i> , 2019, 303, 109925.	2.2	30
80	Implementation and Performance of the Gas Chromatography/Combustion/Isotope Ratio Mass Spectrometry-Based Method for the Confirmatory Analysis of Endogenous Anabolic Steroids during the Rio de Janeiro Olympic and Paralympic Games 2016. <i>Analytical Chemistry</i> , 2019, 91, 11747-11756.	6.5	6
81	Safety, hemodynamic effects, and detection of acute xenon inhalation: rationale for banning xenon from sport. <i>Journal of Applied Physiology</i> , 2019, 127, 1511-1518.	2.5	7
82	Effect of acute and chronic xenon inhalation on erythropoietin, hematological parameters, and athletic performance. <i>Journal of Applied Physiology</i> , 2019, 127, 1503-1510.	2.5	9
83	Development of two complementary LC-HRMS methods for analyzing sotatercept in dried blood spots for doping controls. <i>Bioanalysis</i> , 2019, 11, 923-940.	1.5	16
84	Peptidic drugs and drug candidates in sports drug testing: agents affecting mitochondrial biogenesis or preventing activin receptor II activation. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 9, 22-27.	1.4	5
85	Organ distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine. <i>Forensic Science International</i> , 2019, 303, 109959.	2.2	14
86	Analysis of endogenous steroids in urine by means of multi-immunoaffinity chromatography and isotope ratio mass spectrometry for sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 7563-7571.	3.7	4
87	Detection of the myostatin-neutralizing antibody Domagrozumab in serum by means of Western blotting and LC-HRMS. <i>Drug Testing and Analysis</i> , 2019, 11, 1714-1723.	2.6	11
88	Recent advances in the determination of insulins from biological fluids. <i>Advances in Clinical Chemistry</i> , 2019, 93, 115-167.	3.7	22
89	Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples. <i>Drug Testing and Analysis</i> , 2019, 11, 1755-1760.	2.6	2
90	Studies on the in vivo metabolism of methylstenbolone and detection of novel long term metabolites for doping control analysis. <i>Drug Testing and Analysis</i> , 2019, 11, 1644-1655.	2.6	16

#	ARTICLE	IF	CITATIONS
91	In vitro metabolic profiling of synthetic cannabinoids by pooled human liver microsomes, cytochrome P450 isoenzymes, and <i>Cunninghamella elegans</i> and their detection in urine samples. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 3561-3579.	3.7	15
92	Differing Water Intake and Hydration Status in Three European Countries – A Day-to-Day Analysis. <i>Nutrients</i> , 2019, 11, 773.	4.1	11
93	Does oral fluid contribute to exhaled breath samples collected by means of an electret membrane?. <i>Drug Testing and Analysis</i> , 2019, 11, 1764-1770.	2.6	8
94	The 37th Manfred Donike workshop on doping analysis. <i>Drug Testing and Analysis</i> , 2019, 11, 1587-1588.	2.6	0
95	Detection of black market follistatin 344. <i>Drug Testing and Analysis</i> , 2019, 11, 1675-1697.	2.6	6
96	Is heptaminol a (major) metabolite of octodrine?. <i>Drug Testing and Analysis</i> , 2019, 11, 1761-1763.	2.6	10
97	Phase I metabolic profiling of the synthetic cannabinoids THJ-018 and THJ-2201 in human urine in comparison to human liver microsome and cytochrome P450 isoenzyme incubation. <i>International Journal of Legal Medicine</i> , 2019, 133, 1049-1064.	2.2	8
98	Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. <i>Rapid Communications in Mass Spectrometry</i> , 2019, 33, 371-380.	1.5	16
99	SARCOSYL-PAGE: Optimized Protocols for the Separation and Immunological Detection of PEGylated Proteins. <i>Methods in Molecular Biology</i> , 2019, 1855, 131-149.	0.9	7
100	Annual banned substance review: Analytical approaches in human sports drug testing. <i>Drug Testing and Analysis</i> , 2019, 11, 8-26.	2.6	14
101	Organ distribution of 4-MEC, MDPV, methoxetamine and Δ^9 -PVP: comparison of QuEChERS and SPE. <i>Forensic Toxicology</i> , 2018, 36, 320-333.	2.4	17
102	Analytical challenges in sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 2275-2281.	3.7	12
103	Growth hormone isoform differential mass spectrometry for doping control purposes. <i>Drug Testing and Analysis</i> , 2018, 10, 938-946.	2.6	9
104	Detection of the Human Anti-ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LC-MS/MS. <i>Proteomics - Clinical Applications</i> , 2018, 12, e1700120.	1.6	12
105	Structural elucidation of major selective androgen receptor modulator (SARM) metabolites for doping control. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 698-702.	2.8	13
106	Effects of different exercise intensities in the morning on football performance components in the afternoon. <i>German Journal of Exercise and Sport Research</i> , 2018, 48, 235-244.	1.2	4
107	Unambiguous identification and characterization of a long-term human metabolite of dehydrochloromethyltestosterone. <i>Drug Testing and Analysis</i> , 2018, 10, 1244-1250.	2.6	22
108	Detection of SARMS in doping control analysis. <i>Molecular and Cellular Endocrinology</i> , 2018, 464, 34-45.	3.2	59

#	ARTICLE	IF	CITATIONS
109	Mass spectrometric studies on selective androgen receptor modulators (SARMs) using electron ionization and electrospray ionization/collision-induced dissociation. <i>European Journal of Mass Spectrometry</i> , 2018, 24, 145-156.	1.0	22
110	Equine in vivo -derived metabolites of the SARM LGD-4033 and comparison with human and fungal metabolites. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1074-1075, 91-98.	2.3	21
111	Detection of Sotatercept (ACE011) in human serum by SARPAGE and western single blotting. <i>Drug Testing and Analysis</i> , 2018, 10, 927-937.	2.6	9
112	Annual banned substance review: Analytical approaches in human sports drug testing. <i>Drug Testing and Analysis</i> , 2018, 10, 9-27.	2.6	19
113	Combined detection of the ActRIIAFc fusion proteins Sotatercept (ActRIIAFc) and Luspatercept (modified) Tj ETQq1 1 0.784314 rgBT /Overload <i>Drug Testing and Analysis</i> , 2018, 10, 1714-1721.	2.6	14
114	Analysis of insulin and insulin analogs from dried blood spots by means of liquid chromatography-high resolution mass spectrometry. <i>Drug Testing and Analysis</i> , 2018, 10, 1761-1768.	2.6	31
115	Recent improvements in sports drug testing concerning the initial testing for peptidic drugs (<) Tj ETQq1 1 0.784314 rgBT /Overload <i>Drug Testing and Analysis</i> , 2018, 10, 1755-1760.	2.6	22
116	Effects of 3 Weeks of Oral Low-Dose Cobalt on Hemoglobin Mass and Aerobic Performance. <i>Frontiers in Physiology</i> , 2018, 9, 1289.	2.8	10
117	Studies on their vivometabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls. <i>Drug Testing and Analysis</i> , 2018, 10, 1646-1656.	2.6	17
118	Hydroxyurea therapy modulates sickle cell anemia red blood cell physiology: Impact on RBC deformability, oxidative stress, nitrite levels and nitric oxide synthase signalling pathway. <i>Nitric Oxide - Biology and Chemistry</i> , 2018, 81, 28-35.	2.7	36
119	Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication. <i>International Journal of Legal Medicine</i> , 2018, 132, 1645-1657.	2.2	10
120	Case Study: Atypical <i>13</i>C values of urinary norandrosterone. <i>Drug Testing and Analysis</i> , 2018, 10, 1728-1733.	2.6	9
121	Updated protocols for the detection of Sotatercept and Luspatercept in human serum. <i>Drug Testing and Analysis</i> , 2018, 10, 1708-1713.	2.6	9
122	Analysis of new growth promoting black market products. <i>Growth Hormone and IGF Research</i> , 2018, 41, 1-6.	1.1	11
123	Development and validation of a multidimensional gas chromatography/combustion/isotope ratio mass spectrometry-based test method for analyzing urinary steroids in doping controls. <i>Analytica Chimica Acta</i> , 2018, 1030, 105-114.	5.4	17
124	Xenon elimination kinetics following brief exposure. <i>Drug Testing and Analysis</i> , 2017, 9, 666-670.	2.6	9
125	Human sports drug testing by mass spectrometry. <i>Mass Spectrometry Reviews</i> , 2017, 36, 16-46.	5.4	31
126	GHB-O-12-glucuronide in blood and urine is not a suitable tool for the extension of the detection window after GHB intake. <i>Forensic Toxicology</i> , 2017, 35, 263-274.	2.4	18

#	ARTICLE	IF	CITATIONS
127	Qualitative and Semiquantitative Analysis of Doping Products Seized at the Swiss Border. Substance Use and Misuse, 2017, 52, 742-753.	1.4	27
128	Simultaneous determination of insulin, DesB30 insulin, proinsulin, and C-peptide in human plasma samples by liquid chromatography coupled to high resolution mass spectrometry. Forensic Toxicology, 2017, 35, 106-113.	2.4	20
129	Analysis of taxine B/isotaxine B in a plasma specimen by LC-MS/MS in a case of fatal poisoning: concealed suicide by ingestion of yew (<i>Taxus L.</i>) leaves of a patient with a long-term history of borderline personality disorder. Forensic Toxicology, 2017, 35, 421-427.	2.4	6
130	The atypical excretion profile of meldonium: Comparison of urinary detection windows after single- and multiple-dose application in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, 2017, 138, 175-179.	2.8	12
131	Mass spectrometric characterization of the selective androgen receptor modulator (SARM) YK11 for doping control purposes. Rapid Communications in Mass Spectrometry, 2017, 31, 1175-1183.	1.5	19
132	Expanding analytical options in sports drug testing: Mass spectrometric detection of prohibited substances in exhaled breath. Rapid Communications in Mass Spectrometry, 2017, 31, 1290-1296.	1.5	29
133	Implementation of the prolyl hydroxylase inhibitor Roxadustat (FG4592) and its main metabolites into routine doping controls. Drug Testing and Analysis, 2017, 9, 1768-1778.	2.6	25
134	Screening for adiponectin receptor agonists and their metabolites in urine and dried blood spots. Clinical Mass Spectrometry, 2017, 6, 13-20.	1.9	7
135	Characterization of <i>in vitro</i> generated metabolites of selected peptides $\leq 2\text{ kDa}$ prohibited in sports. Drug Testing and Analysis, 2017, 9, 1799-1803.	2.6	15
136	Epiandrosterone sulfate prolongs the detectability of testosterone, androstenedione, and dihydrotestosterone misuse by means of carbon isotope ratio mass spectrometry. Drug Testing and Analysis, 2017, 9, 1695-1703.	2.6	41
137	Carbon isotope ratios of endogenous steroids in Belgian Blue and Holstein cattle: Method development, reference population studies and application to steroid misuse control. Rapid Communications in Mass Spectrometry, 2017, 31, 1793-1802.	1.5	2
138	Determination of 74 new psychoactive substances in serum using automated in-line solid-phase extraction-liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1064, 124-138.	2.3	36
139	Antibody-based strategies for the detection of Luspatercept (ACE536) in human serum. Drug Testing and Analysis, 2017, 9, 1721-1730.	2.6	16
140	Immunoaffinity techniques coupled to mass spectrometry for the analysis of human peptide hormones: advances and applications. Expert Review of Proteomics, 2017, 14, 799-807.	3.0	20
141	Probing for corticotropin-releasing hormone (CRH) in human blood for doping control purposes using immunoaffinity purification and LC-HRMS/MS. Analytical Methods, 2017, 9, 4304-4310.	2.7	6
142	Determination of LongR 3 -IGF-I, R 3 -IGF-I, Des1-3 IGF-I and their metabolites in human plasma samples by means of LC-MS. Growth Hormone and IGF Research, 2017, 35, 33-39.	1.1	12
143	Development and validation of a HPLC-QTOF-MS method for the determination of GHB- β -O-glucuronide and GHB-4-sulfate in plasma and urine. Forensic Toxicology, 2017, 35, 77-85.	2.4	9
144	Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. Drug Testing and Analysis, 2017, 9, 1372-1384.	2.6	9

#	ARTICLE	IF	CITATIONS
145	Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls. <i>Drug Testing and Analysis</i> , 2017, 9, 61-67.	2.6	16
146	Investigation of the metabolites of the HIF stabilizer FG-4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 134, 228-236.	2.8	20
147	Annual banned-substance review: analytical approaches in human sports drug testing. <i>Drug Testing and Analysis</i> , 2017, 9, 6-29.	2.6	16
148	Applications of Isotope Ratio Mass Spectrometry in Sports Drug Testing Accounting for Isotope Fractionation in Analysis of Biological Samples. <i>Methods in Enzymology</i> , 2017, 596, 403-432.	1.0	18
149	Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls. <i>Drug Testing and Analysis</i> , 2016, 8, 858-863.	2.6	14
150	Analytical detection of trimetazidine produced by metabolic conversion of lomerizine in doping control analysis. <i>Drug Testing and Analysis</i> , 2016, 8, 869-874.	2.6	10
151	Simplifying and expanding the screening for peptides $\leq 2\text{ kDa}$ by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. <i>Journal of Separation Science</i> , 2016, 39, 333-341.	2.5	40
152	Investigation of the selective androgen receptor modulators S1, S4 and S22 and their metabolites in equine plasma using high-resolution mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2016, 30, 833-842.	1.5	20
153	Nickel in equine sports drug testing – pilot study results on urinary nickel concentrations. <i>Rapid Communications in Mass Spectrometry</i> , 2016, 30, 982-984.	1.5	8
154	The 34 th Manfred Donike Workshop on Doping Analysis. <i>Drug Testing and Analysis</i> , 2016, 8, 1108-1108.	2.6	0
155	Sports drug testing using complementary matrices: Advantages and limitations. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 130, 220-230.	2.8	97
156	Analyses of Meldonium (Mildronate) from Blood, Dried Blood Spots (DBS), and Urine Suggest Drug Incorporation into Erythrocytes. <i>International Journal of Sports Medicine</i> , 2016, 37, 500-502.	1.7	27
157	Identification of Selected <i>in vitro</i> -Generated Phase-I Metabolites of the Steroidal Selective Androgen Receptor Modulator MK-0773 for Doping Control Purposes. <i>European Journal of Mass Spectrometry</i> , 2016, 22, 49-59.	1.0	12
158	Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 131, 482-496.	2.8	48
159	Testing for the erythropoiesis-stimulating agent Sotatercept/ACE011 (ActRIIA-Fc) in serum by means of Western blotting and LC-MS. <i>Drug Testing and Analysis</i> , 2016, 8, 1152-1161.	2.6	24
160	Annual banned-substance review: analytical approaches in human sports drug testing. <i>Drug Testing and Analysis</i> , 2016, 8, 7-29.	2.6	36
161	Evaluation of AMGEN clone 9G8A anti-Epo antibody for application in doping control. <i>Drug Testing and Analysis</i> , 2016, 8, 1131-1137.	2.6	3
162	Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination. <i>Forensic Science International</i> , 2016, 267, 166-172.	2.2	27

#	ARTICLE	IF	CITATIONS
163	Genotype-dependent metabolism of exogenous testosterone – new biomarkers result in prolonged detectability. <i>Drug Testing and Analysis</i> , 2016, 8, 1163-1173.	2.6	33
164	Analytics of nonpeptidic erythropoietin mimetic agents in sports drug testing employing high-resolution/high-accuracy liquid chromatography-mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 6431-6442.	3.7	2
165	Optimization of an online heart-cutting multidimensional gas chromatography clean-up step for isotopic ratio mass spectrometry and simultaneous quadrupole mass spectrometry measurements of endogenous anabolic steroid in urine. <i>Drug Testing and Analysis</i> , 2016, 8, 1204-1211.	2.6	22
166	Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis – Potential implications for sports drug testing programs. <i>Rapid Communications in Mass Spectrometry</i> , 2016, 30, 635-651.	1.5	35
167	Mitragynine (Kratom) – monitoring in sports drug testing. <i>Drug Testing and Analysis</i> , 2016, 8, 1114-1118.	2.6	10
168	In vitro elucidation of the metabolic profile of the synthetic cannabinoid receptor agonists JWH-175 and JWH-176. <i>Forensic Toxicology</i> , 2016, 34, 353-362.	2.4	6
169	Myostatin inhibitors in sports drug testing: Detection of myostatin-neutralizing antibodies in plasma/serum by affinity purification and Western blotting. <i>Proteomics - Clinical Applications</i> , 2016, 10, 195-205.	1.6	10
170	Identification and characterization of in vitro and in vivo generated metabolites of the adiponectin receptor agonists AdipoRon and 112254. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 125, 68-76.	2.8	13
171	Solutions Advertised as Erythropoiesis-stimulating Products were Found to Contain Undeclared Cobalt and Nickel Species. <i>International Journal of Sports Medicine</i> , 2016, 37, 82-84.	1.7	13
172	Fully automated determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug testing. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 123, 132-140.	2.8	39
173	Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 3145-3153.	3.7	30
174	Revisiting the metabolism of 19-nortestosterone using isotope ratio and high resolution/high accuracy mass spectrometry. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 162, 80-91.	2.5	20
175	Metabolism of Oral Turinabol by Human Steroid Hormone-Synthesizing Cytochrome P450 Enzymes. <i>Drug Metabolism and Disposition</i> , 2016, 44, 227-237.	3.3	23
176	Methotrexate reduces HbA1c concentration but does not produce chronic accumulation of ZMP in patients with rheumatoid or psoriatic arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 347-355.	1.1	15
177	Potency of Full- Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations. <i>PLoS ONE</i> , 2016, 11, e0150453.	2.5	6
178	Factitious administration of analogue insulin to a 2-year-old child. <i>British Journal of Diabetes</i> , 2016, 16, 82.	0.2	6
179	<i>In vitro</i> Metabolism Studies on the Selective Androgen Receptor Modulator LG121071 and its Implementation into Human Doping Controls Using Liquid Chromatography-Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2015, 21, 27-36.	1.0	19
180	Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. <i>Drug Testing and Analysis</i> , 2015, 7, 919-925.	2.6	35

#	ARTICLE	IF	CITATIONS
181	Complementing the characterization of <i>in vivo</i> generated <i>N</i> -glucuronic acid conjugates of stanozolol by collision cross section computation and analysis. <i>Drug Testing and Analysis</i> , 2015, 7, 1050-1056.	2.6	17
182	Monitoring 2-phenylethylamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls. <i>Drug Testing and Analysis</i> , 2015, 7, 1057-1062.	2.6	9
183	Detection of testosterone esters in blood. <i>Drug Testing and Analysis</i> , 2015, 7, 983-989.	2.6	36
184	Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of <i>in vitro</i> generated phase metabolites for human sports drug testing. <i>Rapid Communications in Mass Spectrometry</i> , 2015, 29, 991-999.	1.5	33
185	Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-MS/MS. <i>Drug Testing and Analysis</i> , 2015, 7, 990-998.	2.6	33
186	Annual banned substance review: analytical approaches in human sports drug testing. <i>Drug Testing and Analysis</i> , 2015, 7, 1-20.	2.6	30
187	Characterization of equine urinary metabolites of selective androgen receptor modulators (SARMs) S1, S4 and S22 for doping control purposes. <i>Drug Testing and Analysis</i> , 2015, 7, 673-683.	2.6	32
188	Studies on the collision-induced dissociation of adipoR agonists after electrospray ionization and their implementation in sports drug testing. <i>Journal of Mass Spectrometry</i> , 2015, 50, 407-417.	1.6	5
189	Formation of the diuretic chlorazanyl from the antimalarial drug proguanil—Implications for sports drug testing. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 208-213.	2.8	10
190	Effects of Exercise on the Urinary Proteome. <i>Advances in Experimental Medicine and Biology</i> , 2015, 845, 121-131.	1.6	17
191	EPOR-Based Purification and Analysis of Erythropoietin Mimetic Peptides from Human Urine by Cys-Specific Cleavage and LC/MS/MS. <i>Journal of the American Society for Mass Spectrometry</i> , 2015, 26, 1617-1625.	2.8	6
192	Determination of Synacthen® in dried blood spots for doping control analysis using liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 4709-4720.	3.7	24
193	“Dilute-and-inject” multi-target screening assay for highly polar doping agents using hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry for sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 5365-5379.	3.7	48
194	Mildronate (Meldonium) in professional sports “ monitoring doping control urine samples using hydrophilic interaction liquid chromatography “ high resolution/high accuracy mass spectrometry. <i>Drug Testing and Analysis</i> , 2015, 7, 973-979.	2.6	48
195	Metabolism of human insulin after subcutaneous administration: A possible means to uncover insulin misuse. <i>Analytica Chimica Acta</i> , 2015, 897, 53-61.	5.4	23
196	Dried blood spots (DBS) in doping controls: a complementary matrix for improved in- and out-of-competition sports drug testing strategies. <i>Analytical Methods</i> , 2015, 7, 7596-7605.	2.7	23
197	Seizures of doping substances at the Swiss Border “ a descriptive investigation. <i>Forensic Science International</i> , 2015, 257, 359-368.	2.2	18
198	Urine analysis concerning xenon for doping control purposes. <i>Rapid Communications in Mass Spectrometry</i> , 2015, 29, 61-66.	1.5	15

#	ARTICLE	IF	CITATIONS
199	Time for change: a roadmap to guide the implementation of the World Anti-Doping Code 2015. <i>British Journal of Sports Medicine</i> , 2014, 48, 801-806.	6.7	20
200	Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. <i>Expert Review of Proteomics</i> , 2014, 11, 663-673.	3.0	26
201	Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes. <i>Drug Testing and Analysis</i> , 2014, 6, 1102-1107.	2.6	12
202	Determination of human insulin and its analogues in human blood using liquid chromatography coupled to ion mobility mass spectrometry (LC-IMS). <i>Drug Testing and Analysis</i> , 2014, 6, 1125-1132.	2.6	62
203	Isolation, Enrichment, and Analysis of Erythropoietins in Anti-Doping Analysis by Receptor-Coated Magnetic Beads and Liquid Chromatography-Mass Spectrometry. <i>Analytical Chemistry</i> , 2014, 86, 12014-12021.	6.5	17
204	Detection of an unknown fusion protein in confiscated black market products. <i>Drug Testing and Analysis</i> , 2014, 6, 1117-1124.	2.6	13
205	Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls. <i>Growth Hormone and IGF Research</i> , 2014, 24, 276-280.	1.1	15
206	Annual banned substance review: analytical approaches in human sports drug testing. <i>Drug Testing and Analysis</i> , 2014, 6, 164-184.	2.6	20
207	Determination of ¹³ C/ ¹² C ratios of endogenous urinary 5-aminoimidazole-4-carboxamide 1 β -ribofuranoside (AICAR). <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 1194-1202.		22
208	Use of dried blood spots in doping control analysis of anabolic steroid esters. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 96, 21-30.	2.8	51
209	Anabolic agents: recent strategies for their detection and protection from inadvertent doping. <i>British Journal of Sports Medicine</i> , 2014, 48, 820-826.	6.7	92
210	Measuring xenon in human plasma and blood by gas chromatography/mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 1501-1506.	1.5	25
211	Isotope dilution mass spectrometric quantification of the prodrug lisdexamfetamine in human urine in doping control analysis. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 781-786.	1.5	6
212	Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 649-659.	2.8	20
213	Quantifying cobalt in doping control urine samples – a pilot study. <i>Drug Testing and Analysis</i> , 2014, 6, 1186-1190.	2.6	26
214	Carbon Isotope Ratio Analysis of Steroids by High-Temperature Liquid Chromatography-Isotope Ratio Mass Spectrometry. <i>Analytical Chemistry</i> , 2014, 86, 2297-2302.	6.5	14
215	Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches. <i>Drug Testing and Analysis</i> , 2014, 6, 1197-1205.	2.6	16
216	Interlaboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured by Mass Spectrometry. <i>Clinical Chemistry</i> , 2014, 60, 541-548.	3.2	96

#	ARTICLE	IF	CITATIONS
217	Identification of black market products and potential doping agents in Germany 2010–2013. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1303-1311.	1.9	84
218	Isolation and characterization of a β -glucuronide of hydroxylated SARM S1 produced using a combination of biotransformation and chemical oxidation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 98, 36-39.	2.8	5
219	Quantification of intact human insulin-like growth factor-1 in serum by nano-ultra-high performance liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 1426-1432.	1.5	30
220	Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 101, 66-83.	2.8	53
221	Glycerol administration before endurance exercise: metabolism, urinary glycerol excretion and effects on doping-relevant blood parameters. <i>Drug Testing and Analysis</i> , 2014, 6, 202-209.	2.6	13
222	Liquid Chromatography-High Resolution/High Accuracy (Tandem) Mass Spectrometry-Based Identification of <i>in vivo</i> Generated Metabolites of the Selective Androgen Receptor Modulator ACP-105 for Doping Control Purposes. <i>European Journal of Mass Spectrometry</i> , 2014, 20, 73-83.	1.0	16
223	Synthesis of Four SIRT1 Activators Based on an Imidazo[1,2-b]thiazole Structure, <i>in vitro</i> Derived Metabolites and Deuterated Analogs. <i>Open Organic Chemistry Journal</i> , 2014, 8, 19-23.	0.9	1
224	Traditional Chinese medicine and sports drug testing: identification of natural steroid administration in doping control urine samples resulting from musk (pod) extracts. <i>British Journal of Sports Medicine</i> , 2013, 47, 109-114.	6.7	37
225	Synthesis, characterization, and detection of new oxandrolone metabolites as long-term markers in sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 8285-8294.	3.7	52
226	Quantification of AICAR-ribotide concentrations in red blood cells by means of LC-MS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 9703-9709.	3.7	19
227	Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing. <i>Drug Testing and Analysis</i> , 2013, 5, 810-818.	2.6	62
228	Hydrogen isotope ratio mass spectrometry and high-resolution/high-accuracy mass spectrometry in metabolite identification studies: Detecting target compounds for sports drug testing. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 1904-1912.	1.5	25
229	Targeting prohibited substances in doping control blood samples by means of chromatographic mass spectrometric methods. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 9655-9667.	3.7	20
230	Mass spectrometric characterization of glucuronides formed by a new concept, combining <i>Cunninghamella elegans</i> with TEMPO. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 84, 278-284.	2.8	8
231	Selective androgen receptor modulators: <i>in vitro</i> and <i>in vivo</i> metabolism and analysis. <i>Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment</i> , 2013, 30, 1517-1526.	2.3	24
232	Detection of small interfering RNA (siRNA) by mass spectrometry procedures in doping controls. <i>Drug Testing and Analysis</i> , 2013, 5, 853-860.	2.6	17
233	Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 35-50.	1.5	12
234	Mass spectrometric studies on the <i>in vitro</i> generated metabolites of SIRT1 activating drugs for doping control purposes. <i>Journal of Mass Spectrometry</i> , 2013, 48, 830-843.	1.6	8

#	ARTICLE	IF	CITATIONS
235	In vitro synthesis and characterisation of three fenoterol sulfoconjugates detected in fenoterol post-administration urine samples. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 9477-9487.	3.7	4
236	Combination of carbon isotope ratio with hydrogen isotope ratio determinations in sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 5455-5466.	3.7	36
237	Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 993-1004.	1.5	8
238	Annual banned-substance review: analytical approaches in human sports drug testing. <i>Drug Testing and Analysis</i> , 2013, 5, 1-19.	2.6	30
239	Does the analysis of the enantiomeric composition of clenbuterol in human urine enable the differentiation of illicit clenbuterol administration from food contamination in sports drug testing?. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 507-512.	1.5	46
240	Effect of changes in the deuterium content of drinking water on the hydrogen isotope ratio of urinary steroids in the context of sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 2911-2921.	3.7	2
241	Monitoring drug residues in donor blood/plasma samples using LC-MS/MS - a pilot study. <i>Drug Testing and Analysis</i> , 2013, 5, 380-383.	2.6	11
242	Post-mortem vitreous humour as potential specimen for detection of insulin analogues by LC-MS/MS. <i>Forensic Science International</i> , 2013, 233, 328-332.	2.2	26
243	Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin. <i>Bioanalysis</i> , 2013, 5, 587-602.	1.5	17
244	Synthesis, Mass Spectrometric Characterization, and Analysis of the PPAR γ Agonist GW1516 and Its Major Human Metabolites: Targets in Sports Drug Testing. <i>Methods in Molecular Biology</i> , 2013, 952, 301-312.	0.9	10
245	Adverse analytical findings with clenbuterol among U-17 soccer players attributed to food contamination issues. <i>Drug Testing and Analysis</i> , 2013, 5, 372-376.	2.6	47
246	Ultrahigh pressure liquid chromatography-(tandem) mass spectrometry in human sports drug testing: Possibilities and limitations. <i>Journal of Chromatography A</i> , 2013, 1292, 38-50.	3.7	41
247	Using electrochemistry for metabolite simulation and synthesis in preventive doping research: application to the Rycal S107 and the PPAR γ -agonist GW1516. <i>Analytical Methods</i> , 2013, 5, 1214.	2.7	1
248	Expanding sports drug testing assays: Mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 1173-1182.	1.5	20
249	AOD-9604 does not influence the WADA hGH isoform immunoassay. <i>Drug Testing and Analysis</i> , 2013, 5, 850-852.	2.6	8
250	The fungus <i>Cunninghamella elegans</i> can produce human and equine metabolites of selective androgen receptor modulators (SARMs). <i>Xenobiotica</i> , 2013, 43, 409-420.	1.1	17
251	Meta-analysis: Effects of glycerol administration on plasma volume, haemoglobin, and haematocrit. <i>Drug Testing and Analysis</i> , 2013, 5, 896-899.	2.6	13
252	Effects of gamma irradiation and 15 days of subsequent ex vivo storage on the cytosolic red blood cell proteome analyzed by 2D-DIGE and Orbitrap MS. <i>Proteomics - Clinical Applications</i> , 2013, 7, 561-570.	1.6	5

#	ARTICLE	IF	CITATIONS
253	RBC-NOS-Dependent S-Nitrosylation of Cytoskeletal Proteins Improves RBC Deformability. PLoS ONE, 2013, 8, e56759.	2.5	135
254	Detection of illegal use of androgens and selective androgen receptor modulators. , 2012, , 517-534.		7
255	Analytical challenges in the detection of peptide hormones for anti-doping purposes. Bioanalysis, 2012, 4, 1577-1590.	1.5	29
256	Detection of Peginesatide in Equine Serum Using Liquid Chromatography-Tandem Mass Spectrometry for Doping Control Purposes. European Journal of Mass Spectrometry, 2012, 18, 407-412.	1.0	6
257	New potential markers for the detection of boldenone misuse. Journal of Steroid Biochemistry and Molecular Biology, 2012, 132, 239-246.	2.5	59
258	Mass spectrometric detection of peginesatide in human urine in doping control analysis. Journal of Pharmaceutical and Biomedical Analysis, 2012, 70, 512-517.	2.8	14
259	Investigations on hydrogen isotope ratios of endogenous urinary steroids: referenceâ€populationâ€based thresholds and proofâ€ofâ€concept. Drug Testing and Analysis, 2012, 4, 717-727.	2.6	32
260	Influence of repeated subcutaneous Gâ€CSF injections on selected blood parameters relevant for monitoring programmes in sports drug testing. Drug Testing and Analysis, 2012, 4, 798-802.	2.6	3
261	Storageâ€induced changes of the cytosolic red blood cell proteome analyzed by 2D DIGE and highâ€resolution/highâ€accuracy MS. Proteomics, 2012, 12, 3263-3272.	2.2	17
262	Immunoaffinity purification of peptide hormones prior to liquid chromatographyâ€mass spectrometry in doping controls. Methods, 2012, 56, 230-235.	3.8	85
263	Investigations of the microbial transformation of cortisol to prednisolone in urine samples. Journal of Steroid Biochemistry and Molecular Biology, 2012, 129, 54-60.	2.5	34
264	Metabolism of Growth Hormone Releasing Peptides. Analytical Chemistry, 2012, 84, 10252-10259.	6.5	47
265	Validated hemoglobinâ€depletion approach for red blood cell lysate proteome analysis by means of 2<sc>D PAGE</sc> and <sc>O</sc>rbitrapp <sc>MS</sc>. Electrophoresis, 2012, 33, 2537-2545.	2.4	19
266	Characterization of InÂVitro Synthesized Equine Metabolites of the Selective Androgen Receptor Modulators S24 and S4. Journal of Equine Veterinary Science, 2012, 32, 562-568.	0.9	13
267	Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry. Journal of Chromatography A, 2012, 1259, 251-257.	3.7	54
268	Simultaneous determination and validated quantification of human insulin and its synthetic analogues in human blood serum by immunoaffinity purification and liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry, 2012, 404, 1813-1822.	3.7	65
269	Clenbuterol â€ regional food contamination a possible source for inadvertent doping in sports. Drug Testing and Analysis, 2012, 4, 534-538.	2.6	62
270	Detection of EPOâ€Fc fusion protein in human blood: Screening and confirmation protocols for sports drug testing. Drug Testing and Analysis, 2012, 4, 818-829.	2.6	24

#	ARTICLE	IF	CITATIONS
271	Identification and characterization of urinary prenylamine metabolites by means of liquid chromatography-tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2012, 4, 701-716.	2.6	6
272	Recent instrumental progress in mass spectrometry: advancing resolution, accuracy, and speed of drug detection. <i>Drug Testing and Analysis</i> , 2012, 4, 242-245.	2.6	26
273	Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. <i>Drug Testing and Analysis</i> , 2012, 4, 830-845.	2.6	74
274	Analysis of octopamine in human doping control samples. <i>Biomedical Chromatography</i> , 2012, 26, 610-615.	1.7	11
275	Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 2715-2724.	3.7	58
276	Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 1279-1289.	3.7	136
277	Plasticizers excreted in urine: indication of autologous blood transfusion in sports. <i>Transfusion</i> , 2012, 52, 647-657.	1.6	35
278	Sports drug testing: Analytical aspects of selected cases of suspected, purported, and proven urine manipulation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 57, 26-32.	2.8	33
279	Measuring insulin in human vitreous humour using LC-MS/MS. <i>Drug Testing and Analysis</i> , 2012, 4, 53-56.	2.6	42
280	' <i>Drug Testing and Analysis</i> ' one-year impact factor. <i>Drug Testing and Analysis</i> , 2012, 4, 1-1.	2.6	1
281	Annual banned-substance review: analytical approaches in human sports drug testing. <i>Drug Testing and Analysis</i> , 2012, 4, 2-16.	2.6	14
282	Structure Elucidation of the Diagnostic Product Ion at m/z 97 Derived from Androst-4-en-3-One-Based Steroids by ESI-CID and IRMPD Spectroscopy. <i>Journal of the American Society for Mass Spectrometry</i> , 2012, 23, 537-546.	2.8	23
283	Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS. <i>Analyst</i> , The, 2011, 136, 1003-1012.	3.5	57
284	Determination of Vasopressin and Desmopressin in urine by means of liquid chromatography coupled to quadrupole time-of-flight mass spectrometry for doping control purposes. <i>Analytica Chimica Acta</i> , 2011, 707, 107-113.	5.4	47
285	Evaluation of commercially available assays for the measurement of equine insulin. <i>Domestic Animal Endocrinology</i> , 2011, 41, 81-90.	1.6	58
286	Doping control analysis of selected peptide hormones using LC-MS(/MS). <i>Forensic Science International</i> , 2011, 213, 35-41.	2.2	39
287	Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. <i>Drug Testing and Analysis</i> , 2011, 3, 609-620.	2.6	113
288	Annual banned-substance review: analytical approaches in human sports drug testing. <i>Drug Testing and Analysis</i> , 2011, 3, 1-14.	2.6	44

#	ARTICLE	IF	CITATIONS
289	Trafficking of drug candidates relevant for sports drug testing: Detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. <i>Drug Testing and Analysis</i> , 2011, 3, 331-336.	2.6	45
290	RNA interference for performance enhancement and detection in doping control. <i>Drug Testing and Analysis</i> , 2011, 3, 661-667.	2.6	9
291	Dried blood spots (DBS) for doping control analysis. <i>Drug Testing and Analysis</i> , 2011, 3, 806-813.	2.6	42
292	Zeranol: doping offence or mycotoxin? A case-related study. <i>Drug Testing and Analysis</i> , 2011, 3, 777-783.	2.6	22
293	Urinary excretion of exogenous glycerol administration at rest. <i>Drug Testing and Analysis</i> , 2011, 3, 877-882.	2.6	13
294	Identification of fibroblast growth factor 1 (FGF1) in a black market product. <i>Drug Testing and Analysis</i> , 2011, 3, 791-797.	2.6	16
295	Development of liquid chromatography-tandem mass spectrometry-based analytical assays for the determination of HIF stabilizers in preventive doping research. <i>Drug Testing and Analysis</i> , 2011, 3, 756-770.	2.6	27
296	High-throughput screening for various classes of doping agents using a new "dilute-and-shoot" liquid chromatography-tandem mass spectrometry multi-target approach. <i>Drug Testing and Analysis</i> , 2011, 3, 836-850.	2.6	67
297	Di(2-ethylhexyl)phthalate metabolites as markers for blood transfusion in doping control: Intra-individual variability of urinary concentrations. <i>Drug Testing and Analysis</i> , 2011, 3, 892-895.	2.6	13
298	Screening for benfluorex and its major urinary metabolites in routine doping controls. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 543-551.	3.7	11
299	Rapid determination of urinary di(2-ethylhexyl) phthalate metabolites based on liquid chromatography/tandem mass spectrometry as a marker for blood transfusion in sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 517-528.	3.7	36
300	Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 507-516.	3.7	83
301	Current role of LC-MS(/MS) in doping control. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 405-420.	3.7	86
302	Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 493-505.	3.7	66
303	Anti-doping analysis. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 387-388.	3.7	4
304	Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator Sâ€22 to identify potential targets for routine doping controls. <i>Rapid Communications in Mass Spectrometry</i> , 2011, 25, 2187-2195.	1.5	38
305	Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes. <i>Rapid Communications in Mass Spectrometry</i> , 2011, 25, 2115-2123.	1.5	33
306	Investigation of the <i>in vitro</i> metabolism of the emerging drug candidate S107 for doping-preventive purposes. <i>Journal of Mass Spectrometry</i> , 2011, 46, 112-130.	1.6	33

#	ARTICLE	IF	CITATIONS
307	Wiley-Interscience Series in Mass Spectrometry. , 2010, , 361-361.		1
308	Mass Spectrometry-Based Characterization of New Drugs and Methods of Performance Manipulation in Doping Control Analysis. European Journal of Mass Spectrometry, 2010, 16, 301-312.	1.0	12
309	Identification of the growth hormone-releasing peptide (GHRP) in a nutritional supplement. Drug Testing and Analysis, 2010, 2, 144-148.	2.6	52
310	Annual banned substance review: analytical approaches in human sports drug testing. Drug Testing and Analysis, 2010, 2, 149-161.	2.6	15
311	Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the cologne doping control laboratory 2009. Drug Testing and Analysis, 2010, 2, 533-537.	2.6	92
312	Characterization of <i>in vitro</i> generated metabolites of the selective androgen receptor modulators SARM1 and SARM2 and <i>in vivo</i> comparison to post-administration canine urine specimens. Drug Testing and Analysis, 2010, 2, 589-598.	2.6	41
313	Reporting and managing elevated testosterone/epitestosterone ratios-Novel aspects after five years' experience. Drug Testing and Analysis, 2010, 2, 637-642.	2.6	26
314	Characterization of two major urinary metabolites of the PPAR α -agonist GW1516 and implementation of the drug in routine doping controls. Analytical and Bioanalytical Chemistry, 2010, 396, 2479-2491.	3.7	43
315	Quantification of urinary AICAR concentrations as a matter of doping controls. Analytical and Bioanalytical Chemistry, 2010, 396, 2899-2908.	3.7	34
316	Anabolic, doping, and lifestyle drugs, and selected metabolites in wastewater detection, quantification, and behaviour monitored by high-resolution MS and MS n before and after sewage treatment. Analytical and Bioanalytical Chemistry, 2010, 398, 1207-1229.	3.7	61
317	Mass spectrometric detection of siRNA in plasma samples for doping control purposes. Analytical and Bioanalytical Chemistry, 2010, 398, 1305-1312.	3.7	22
318	In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Analytical and Bioanalytical Chemistry, 2010, 398, 2141-2153.	3.7	131
319	Analysis of selective androgen receptor modulators by gas chromatography-microchip atmospheric pressure photoionization-mass spectrometry. Journal of the American Society for Mass Spectrometry, 2010, 21, 310-316.	2.8	21
320	Effects of endurance exercise on the urinary proteome analyzed by 2D PAGE and Orbitrap MS. Proteomics - Clinical Applications, 2010, 4, 568-576.	1.6	24
321	Comprehensive plasma screening for known and unknown substances in doping controls. Rapid Communications in Mass Spectrometry, 2010, 24, 1124-1132.	1.5	60
322	Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (SARM4) for routine doping control purposes. Rapid Communications in Mass Spectrometry, 2010, 24, 2245-2254.	1.5	48
323	Determination of $^{13}C/^{12}C$ ratios of endogenous urinary steroids excreted as sulpho conjugates. Rapid Communications in Mass Spectrometry, 2010, 24, 3171-3181.	1.5	46
324	Detection of Surreptitious Administration of Analog Insulin to an 8-Week-Old Infant. Pediatrics, 2010, 125, e1236-e1240.	2.1	39

#	ARTICLE	IF	CITATIONS
325	Stimulants and Doping in Sport. <i>Endocrinology and Metabolism Clinics of North America</i> , 2010, 39, 89-105.	3.2	28
326	SERMs and SARMS: Detection of their activities with yeast based bioassays. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 118, 85-92.	2.5	32
327	Detection of His-tagged Long-R3-IGF-I in a black market product. <i>Growth Hormone and IGF Research</i> , 2010, 20, 386-390.	1.1	33
328	Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. <i>Journal of Mass Spectrometry</i> , 2009, 44, 442-460.	1.6	56
329	Doping control analysis of emerging drugs in human plasma – identification of GW501516, Sâ€107, JTVâ€519, and Sâ€40503. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 1139-1146.	1.5	34
330	Determination of the deuterium/hydrogen ratio of endogenous urinary steroids for doping control purposes. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 1917-1926.	1.5	31
331	Electron ionization mass spectrometry of the ryanodine receptor-based Ca ²⁺ -channel stabilizer S-107 and its implementation into routine doping control. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 2363-2370.	1.5	10
332	Determination of Synacthen in urine for sports drug testing by means of nanoâ€ultraâ€performance liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 2669-2674.	1.5	38
333	Detection and pharmacokinetics of tetrahydrogestrinone in horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2009, 32, 197-202.	1.3	10
334	Unusual mass spectrometric dissociation pathway of protonated isoquinoline-3-carboxamides due to multiple reversible water adduct formation in the gas phase. <i>Journal of the American Society for Mass Spectrometry</i> , 2009, 20, 2034-2048.	2.8	43
335	Insulin. <i>Handbook of Experimental Pharmacology</i> , 2009, , 209-226.	1.8	45
336	Temporal indication of cannabis use by means of THC glucuronide determination. <i>Drug Testing and Analysis</i> , 2009, 1, 505-510.	2.6	26
337	Screening for the calstabinâ€ryanodine receptor complex stabilizers JTVâ€519 and Sâ€107 in doping control analysis. <i>Drug Testing and Analysis</i> , 2009, 1, 32-42.	2.6	15
338	Proteolysis and autolysis of proteases and the detection of degradation products in doping control. <i>Drug Testing and Analysis</i> , 2009, 1, 81-86.	2.6	24
339	Detection of the protease Bacillolysin in dopingâ€control urine samples. <i>Drug Testing and Analysis</i> , 2009, 1, 143-145.	2.6	12
340	Sensitive and fast identification of urinary human, synthetic and animal insulin by means of nanoâ€UPLC coupled with highâ€resolution/highâ€accuracy mass spectrometry. <i>Drug Testing and Analysis</i> , 2009, 1, 219-227.	2.6	72
341	Application of FAIMS to anabolic androgenic steroids in sport drug testing. <i>Drug Testing and Analysis</i> , 2009, 1, 545-553.	2.6	44
342	Comparison of the urinary protein patterns of athletes by 2Dâ€gel electrophoresis and mass spectrometryâ€a pilot study. <i>Drug Testing and Analysis</i> , 2009, 1, 382-386.	2.6	21

#	ARTICLE	IF	CITATIONS
343	Terbutaline sulfoconjugate: characterization and urinary excretion monitored by LC/ESI-MS/MS. Drug Testing and Analysis, 2009, 1, 568-575.	2.6	18
344	Annual banned substance review: the Prohibited List 2008 analytical approaches in human sports drug testing. Drug Testing and Analysis, 2009, 1, 4-13.	2.6	13
345	Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) Sâ€4 (Andarine) in a black market product. Drug Testing and Analysis, 2009, 1, 387-392.	2.6	57
346	Identification of Human Pituitary Growth Hormone Variants by Mass Spectrometry. Journal of Proteome Research, 2009, 8, 1071-1076.	3.7	40
347	Doping control analysis of trenbolone and related compounds using liquid chromatography-tandem mass spectrometry. Steroids, 2009, 74, 315-321.	1.8	31
348	Doping Control Analysis of Metamfepramone and Two Major Metabolites Using Liquid Chromatography-Tandem Mass Spectrometry. European Journal of Mass Spectrometry, 2009, 15, 507-515.	1.0	8
349	Synthetic Anabolic Agents: Steroids and Nonsteroidal Selective Androgen Receptor Modulators. Handbook of Experimental Pharmacology, 2009, , 99-126.	1.8	24
350	Mass Spectrometry-Based Analysis of IGF-1 and hGH. Handbook of Experimental Pharmacology, 2009, , 201-207.	1.8	13
351	Induction of micronuclei in V79 cells by the anabolic doping steroids tetrahydrogestrinone and trenbolone. Archives of Toxicology, 2008, 82, 257-263.	4.2	23
352	Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS. Analytical and Bioanalytical Chemistry, 2008, 391, 251-261.	3.7	40
353	Insulins in equine urine: qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horse racing. Rapid Communications in Mass Spectrometry, 2008, 22, 355-362.	1.5	36
354	Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 477-485.	1.5	103
355	Determination of ¹³ C/ ¹² C ratios of endogenous urinary steroids: method validation, reference population and application to doping control purposes. Rapid Communications in Mass Spectrometry, 2008, 22, 2161-2175.	1.5	151
356	Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 2471-2478.	1.5	36
357	Mass spectrometry of hydantoin-derived selective androgen receptor modulators. Journal of Mass Spectrometry, 2008, 43, 639-650.	1.6	32
358	Liquid chromatographic mass spectrometric analysis of glucuronide-conjugated anabolic steroid metabolites: method validation and interlaboratory comparison. Journal of Mass Spectrometry, 2008, 43, 965-973.	1.6	55
359	Mass spectrometry of selective androgen receptor modulators. Journal of Mass Spectrometry, 2008, 43, 865-876.	1.6	66
360	Nutritional supplements cross-contaminated and faked with doping substances. Journal of Mass Spectrometry, 2008, 43, 892-902.	1.6	319

#	ARTICLE	IF	CITATIONS
361	Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS. <i>Journal of Mass Spectrometry</i> , 2008, 43, 908-915.	1.6	62
362	Factors influencing the steroid profile in doping control analysis. <i>Journal of Mass Spectrometry</i> , 2008, 43, 877-891.	1.6	227
363	Mass spectrometric determination of insulins and their degradation products in sports drug testing. <i>Mass Spectrometry Reviews</i> , 2008, 27, 35-50.	5.4	98
364	Detection of recombinant growth hormone in human plasma by a 2D PAGE method. <i>Electrophoresis</i> , 2008, 29, 4495-4502.	2.4	19
365	Rapid screening of polysaccharide-based plasma volume expanders dextran and hydroxyethyl starch in human urine by liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2008, 22, 695-701.	1.7	25
366	Gas phase reaction of substituted isoquinolines to carboxylic acids in ion trap and triple quadrupole mass spectrometers after electrospray ionization and collision-induced dissociation. <i>Journal of the American Society for Mass Spectrometry</i> , 2008, 19, 151-158.	2.8	30
367	New drugs and methods of doping and manipulation. <i>Drug Discovery Today</i> , 2008, 13, 59-66.	6.4	38
368	Leistungssteigernde Substanzen im LC-MS/MS. <i>Nachrichten Aus Der Chemie</i> , 2008, 56, 910-913.	0.0	0
369	Enzyme-assisted synthesis and structure characterization of glucuronide conjugates of eleven anabolic steroid metabolites. <i>Steroids</i> , 2008, 73, 257-265.	1.8	46
370	Aryl-Propionamide-Derived Selective Androgen Receptor Modulators: Liquid Chromatography-Tandem Mass Spectrometry Characterization of the in Vitro Synthesized Metabolites for Doping Control Purposes. <i>Drug Metabolism and Disposition</i> , 2008, 36, 571-581.	3.3	71
371	Analysis of Confiscated Black Market Drugs Using Chromatographic and Mass Spectrometric Approaches. <i>Journal of Analytical Toxicology</i> , 2008, 32, 232-240.	2.8	62
372	Use of an Electrochemically Synthesised Metabolite of a Selective Androgen Receptor Modulator for Mass Spectrometry-Based Sports Drug Testing. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 163-170.	1.0	30
373	Illicit organogenesis. <i>Organogenesis</i> , 2008, 4, 264-271.	1.2	5
374	Determination of the prevalence of anabolic steroids, stimulants, and selected drugs subject to doping controls among elite sport students using analytical chemistry. <i>Journal of Sports Sciences</i> , 2008, 26, 1059-1065.	2.0	34
375	Discrimination of Recombinant and Endogenous Urinary Erythropoietin by Calculating Relative Mobility Values from SDS Gels. <i>International Journal of Sports Medicine</i> , 2008, 29, 1-6.	1.7	75
376	Quantitative Analysis of Urinary Glycerol Levels for Doping Control Purposes Using Gas Chromatography-Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 117-124.	1.0	30
377	Screening for Two Selective Androgen Receptor Modulators Using Gas Chromatography-Mass Spectrometry in Doping Control Analysis. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 153-161.	1.0	29
378	Identification and Quantification of the Osmodiuretic Mannitol in Urine for Sports Drug Testing Using Gas Chromatography-Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 127-133.	1.0	17

#	ARTICLE	IF	CITATIONS
379	Doping Control Analysis of Methoxyphenamine Using Liquid Chromatography-Tandem Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 145-152.	1.0	11
380	Screening of In Vitro Synthesised Metabolites of 4,9,11-Trien-3-One Steroids by Liquid Chromatography-Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 181-189.	1.0	22
381	Determination of Selected Stimulants in Urine for Sports Drug Analysis by Solid Phase Extraction via Cation Exchange and Means of Liquid Chromatography-Tandem Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 135-143.	1.0	21
382	Emerging Drugs - Potential for Misuse in Sport and Doping Control Detection Strategies. <i>Mini-Reviews in Medicinal Chemistry</i> , 2007, 7, 533-539.	2.4	31
383	Proteases in Doping Control Analysis. <i>International Journal of Sports Medicine</i> , 2007, 28, 545-549.	1.7	39
384	Detection of Homologous Blood Transfusion. <i>International Journal of Sports Medicine</i> , 2007, 28, 633-637.	1.7	31
385	Detection of Dehydroepiandrosterone Misuse by Means of Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2007, 13, 419-426.	1.0	27
386	Determination of Tuaminoheptane in Doping Control Urine Samples. <i>European Journal of Mass Spectrometry</i> , 2007, 13, 213-221.	1.0	17
387	Doping-Control Analysis of the 5 α -Reductase Inhibitor Finasteride: Determination of Its Influence on Urinary Steroid Profiles and Detection of Its Major Urinary Metabolite. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 236-247.	2.0	44
388	Metabolism of 4-hydroxyandrostenedione and 4-hydroxytestosterone: Mass spectrometric identification of urinary metabolites. <i>Steroids</i> , 2007, 72, 278-286.	1.8	34
389	Mass spectrometric identification of peptide hormones in doping-control analysis. <i>Analyst, The</i> , 2007, 132, 287-291.	3.5	33
390	Mass Spectrometric Identification of Degradation Products of Insulin and Its Long-Acting Analogues in Human Urine for Doping Control Purposes. <i>Analytical Chemistry</i> , 2007, 79, 2518-2524.	6.5	75
391	Mass spectrometry in sports drug testing: Structure characterization and analytical assays. <i>Mass Spectrometry Reviews</i> , 2007, 26, 79-107.	5.4	178
392	Recommended criteria for the mass spectrometric identification of target peptides and proteins (<8 kDa) in sports drug testing. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 297-304.	1.5	41
393	Screening for 2 α -quinolinone-derived selective androgen receptor agonists in doping control analysis. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 3477-3486.	1.5	48
394	Long-term engraftment following transplantation of pig pancreatic primordia into non-immunosuppressed diabetic rhesus macaques. <i>Xenotransplantation</i> , 2007, 14, 591-602.	2.8	49
395	Detection of manipulation in doping control urine sample collection: a multidisciplinary approach to determine identical urine samples. <i>Analytical and Bioanalytical Chemistry</i> , 2007, 388, 1539-1543.	3.7	38
396	Current role of LC-MS(/MS) in doping control. <i>Analytical and Bioanalytical Chemistry</i> , 2007, 388, 1351-1358.	3.7	75

#	ARTICLE	IF	CITATIONS
397	Doping Control Analysis of Intact Rapid-Acting Insulin Analogues in Human Urine by Liquid Chromatography-Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2006, 78, 1897-1903.	6.5	91
398	Determination of the origin of urinary norandrosterone traces by gas chromatography combustion isotope ratio mass spectrometry. <i>Analyst, The</i> , 2006, 131, 1021-1026.	3.5	53
399	Tetrahydrogestrinone is a potent but unselective binding steroid and affects glucocorticoid signalling in the liver. <i>Toxicology Letters</i> , 2006, 164, 16-23.	0.8	28
400	Determination of N-Desmethyl- and N-Bisdesmethyl Metabolites of Sibutramine in Doping Control Analysis Using Liquid Chromatography-Tandem Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2006, 12, 129-136.	1.0	30
401	Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 870-876.	1.5	77
402	Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 1954-1962.	1.5	47
403	Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 2252-2258.	1.5	114
404	Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 3393-3402.	1.5	22
405	Determination of Synacthen in human plasma using immunoaffinity purification and liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 3551-3556.	1.5	38
406	Detection of Stanozolol and Its Major Metabolites in Human Urine by Liquid Chromatography-Tandem Mass Spectrometry. <i>Chromatographia</i> , 2006, 64, 441-446.	1.3	33
407	Quantitative Determination of Adrenaline and Noradrenaline in Urine Using Liquid Chromatography-Tandem Mass Spectrometry. <i>Chromatographia</i> , 2006, 64, 587-591.	1.3	21
408	Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography-atmospheric pressure ionization-tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2006, 41, 332-338.	1.6	20
409	Impact of recent biochemical findings on the determination of free and bioavailable testosterone: evaluation and proposal for clinical use / Auswirkungen neuer biochemischer Befunde auf die Bestimmung von freiem und bioverfügbarem Testosteron: Evaluierung und Vorschlag für den klinischen Einsatz. <i>Das Medizinische Laboratorium</i> , 2006, 30, 492-505.	0.0	1
410	Analytik modifizierter Steroidhormone mittels Flüssigkeitschromatographie/Tandem-Massenspektrometrie Analysis of modified steroid hormones using liquid chromatography/tandem mass spectrometry. <i>Das Medizinische Laboratorium</i> , 2006, 30, 26-32.	0.0	2
411	Identification of Fentanyl, Alfentanil, Sufentanil, Remifentanil and Their Major Metabolites in Human Urine by Liquid Chromatography/Tandem Mass Spectrometry for Doping Control Purposes. <i>European Journal of Mass Spectrometry</i> , 2005, 11, 419-427.	1.0	49
412	Mass spectrometric analysis of androstan-17 β -ol-3-one and androstadiene-17 β -ol-3-one isomers. <i>Journal of the American Society for Mass Spectrometry</i> , 2005, 16, 1660-1669.	2.8	48
413	Quantification of Clenbuterol in Human Plasma and Urine by Liquid Chromatography-Tandem Mass Spectrometry. <i>Chromatographia</i> , 2005, 62, 435-439.	1.3	34
414	Examples of Doping Control Analysis by Liquid Chromatography-Tandem Mass Spectrometry: Ephedrine, α -Receptor Blocking Agents, Diuretics, Sympathomimetics, and Cross-Linked Hemoglobins. <i>Journal of Chromatographic Science</i> , 2005, 43, 22-31.	1.4	56

#	ARTICLE	IF	CITATIONS
415	Characterization of chemically modified steroids for doping control purposes by electrospray ionization tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2005, 40, 494-502.	1.6	71
416	Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2005, 40, 955-962.	1.6	127
417	Identification of oral antidiabetics and their metabolites in human urine by liquid chromatography/tandem mass spectrometry-a matter for doping control analysis. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 928-936.	1.5	19
418	Mass spectrometry of stanozolol and its analogues using electrospray ionization and collision-induced dissociation with quadrupole-linear ion trap and linear ion trap-orbitrap hybrid mass analyzers. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 3369-3378.	1.5	73
419	Mass Spectrometry in Doping Control Analysis. <i>Current Organic Chemistry</i> , 2005, 9, 825-848.	1.6	43
420	Identification and Characterization of Peptides and Proteins in Doping Control Analysis. <i>Current Proteomics</i> , 2005, 2, 191-208.	0.3	29
421	Qualitative Determination of Synthetic Analogues of Insulin in Human Plasma by Immunoaffinity Purification and Liquid Chromatography-Tandem Mass Spectrometry for Doping Control Purposes. <i>Analytical Chemistry</i> , 2005, 77, 3579-3585.	6.5	105
422	Electrospray ionization mass spectrometric characterization and quantitation of xanthine derivatives using isotopically labelled analogues: an application for equine doping control analysis. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 1553-1560.	1.5	28
423	N-methyl-N-Trimethylsilyltrifluoroacetamide-Promoted Synthesis and Mass Spectrometric Characterization of Deuterated Ephedrines. <i>European Journal of Mass Spectrometry</i> , 2004, 10, 673-681.	1.0	14
424	Liquid chromatography/electrospray ionization tandem mass spectrometric screening and confirmation methods for β -agonists in human or equine urine. <i>Journal of Mass Spectrometry</i> , 2003, 38, 1197-1206.	1.6	87
425	Effect of the location of hydrogen abstraction on the fragmentation of diuretics in negative electrospray ionization mass spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2003, 14, 658-670.	2.8	23
426	Doping Control Analysis of Bovine Hemoglobin-Based Oxygen Therapeutics in Human Plasma by LC-ESI-MS/MS. <i>Analytical Chemistry</i> , 2003, 75, 3287-3293.	6.5	40
427	Urinary Concentrations of Morphine and Codeine After Consumption of Poppy Seeds. <i>Journal of Analytical Toxicology</i> , 2003, 27, 53-56.	2.8	51
428	Mass Spectrometric Behavior of Thiazide-Based Diuretics after Electrospray Ionization and Collision-Induced Dissociation. <i>Analytical Chemistry</i> , 2002, 74, 3802-3808.	6.5	30
429	Mass spectrometry of steroid glucuronide conjugates. I. Electron impact fragmentation of 5α -/ 5β -androstan- 3α -ol-17-one glucuronides, 5α -estran- 3α -ol-17-one glucuronide and deuterium-labelled analogues. <i>Journal of Mass Spectrometry</i> , 2001, 36, 159-168.	1.6	28
430	Mass spectrometry of steroid glucuronide conjugates. II-Electron impact fragmentation of 3-keto-4-en- and 3-keto- 5α -steroid-17-O- β glucuronides and 5α -steroid- 3α , 17β -diol 3- and 17-glucuronides. <i>Journal of Mass Spectrometry</i> , 2001, 36, 998-1012.	1.6	18
431	High speed determination of beta-receptor blocking agents in human urine by liquid chromatography/tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2001, 15, 393-402.	1.7	56
432	Detection of the plasma volume expander hydroxyethyl starch in human urine. <i>Biomedical Applications</i> , 2000, 744, 345-350.	1.7	40

#	ARTICLE	IF	CITATIONS
433	Performance-Enhancing Drugs. , 0, , 283-303.		1